Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	2	159
Total, all-cause mortality	Sotagliflozin 400 mg	1	317
Total, all-cause mortality	Sotagliflozin 200 mg	0	159
Total, all-cause mortality	Glimepiride	2	317
Total, other adverse events	Placebo	30	159
Total, other adverse events	Sotagliflozin 400 mg	49	317
Total, other adverse events	Sotagliflozin 200 mg	21	159
Total, other adverse events	Glimepiride	22	317
Total, serious adverse events	Placebo	11	159
Total, serious adverse events	Sotagliflozin 400 mg	17	317
Total, serious adverse events	Sotagliflozin 200 mg	11	159
Total, serious adverse events	Glimepiride	14	317

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03332771/event-totals